A Phase 4 interventional study of Spectralis® SD-OCT, Heidelberg Engineering GmbH, H in Glaucoma Patients and Healthy Controls, sponsored by University of Zurich. Terminated at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-10.
Sponsored by University of Zurich · Phase 4, Interventional, and Diagnostic
To assess the reproducibility of Spectral-Domain-OCT (SD-OCT) retinal nerve fiber layer thickness (RNFL) thickness measurements in healthy volunteers and patients with glaucoma and to compare these results to conventional Time-Domain-OCT (TD-OCT).
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 50 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →University of Zurich is the lead sponsor of 1,030 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion criteria: control group:
age 18yo or older, healthy
glaucom group: age 18yo or older, diagnosis of primary open angle glaucoma (POAG)
Exclusion criteria: Exclusion criteria in the control group were history of glaucoma, history of any other ocular disease, or intraocular pressure greater than 21mmHg. Exclusion criteria in the glaucoma group were history of other optic neuropathies.
or severe optic media opacities.
reproducibility of retinal nerve fiber layer thickness measurement
This study is terminated, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Zurich